Skip to main content
Ajjai Alva, MD, Oncology, Ann Arbor, MI

Ajjai Shivaram Alva MD

Genitourinary Oncology, Hematologic Oncology


Associate Professor

Join to View Full Profile
  • 1500 E Medical Center DrB1 Floor Cancer Recp DAnn Arbor, MI 48109

  • Phone+1 734-647-8903

Dr. Alva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Michigan
    University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2010
  • St Agnes HealthCare
    St Agnes HealthCareResidency, Internal Medicine, 2004 - 2007
  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 2000

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2007 - 2025
  • IN State Medical License
    IN State Medical License 2010 - 2013
  • TX State Medical License
    TX State Medical License 2010 - 2013
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors  
    Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
    Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
  • Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma  
    Aaron M Udager, Andrew S Mcdaniel, Simpa S Salami, Samuel D Kaffenberger, Jeffrey S Montgomery, Alon Z Weizer, Zachery R Reichert, Ajjai S Alva, Arul M Chinnaiyan, Sco..., European Urology
  • Join now to see all

Lectures

  • Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utiliza... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

  • Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
    Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney CancerOctober 12th, 2017

Grant Support

  • Biomarker-Based Tools for Treatment Response Decision Support of Bladder CancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2019–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: